Dear Duke Health and Duke University colleagues and staff:

The FDA is planning to review the interim safety and efficacy data for the Pfizer/BioNTech COVID-19 vaccine on December 10th and the Moderna vaccine on December 17th as part of the process to consider COVID-19 vaccines for an emergency use authorization. We anticipate that the FDA could move quickly so we are preparing for an expected early shipment of the Pfizer vaccine to Duke, along with final guidance from the FDA, later this month.

Based on guidelines developed by the state, Duke healthcare workers who are most likely to be exposed to COVID-19 (also known as SARS-CoV-2) in the course of fulfilling their job responsibilities will be among the first group eligible to receive a vaccine. This includes employees in both clinical and research areas.

Read the full message that was sent to all Duke Health and Duke University faculty and staff on Friday, Dec. 4, 2020.